Urokinase-type plasminogen activator regulates cranial neural crest cell migration in vitro

被引:0
|
作者
Agrawal, M [1 ]
Brauer, PR [1 ]
机构
[1] CREIGHTON UNIV,SCH MED,DEPT BIOMED SCI,OMAHA,NE 68178
关键词
neural crest; migration; plasminogen activator; transforming growth factor-beta;
D O I
10.1002/(SICI)1097-0177(199611)207:3<281::AID-AJA5>3.3.CO;2-9
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
Proper migration and differentiation of neural crest (NC) cells are required for normal development of craniofacial structures, heart and great vessels, sensory and autonomic nervous systems, and other organs within vertebrate embryos. Serine-protease inhibitors reduce NC cell migration in vitro, suggesting the extracellular proteases are important mediators of NC cell migration, While plasminogen activator activity levels are high in NC cells relative to other embryonic tissues, its ability to regulate NC cell migration has not been specifically tested in vivo or in vitro. In this study, we show urokinase-type plasminogen activator (uPA) regulates NC cell migration in vitro through its ability to convert plasminogen to plasmin,. Using a transfilter migration assay, NC cell migration was measured in the presence or absence of plasminogen, Our results showed that plasminogen significantly enhanced NC cell migration. This increase could not be attributed to differences in initial NC cell attachment or cytotoxicity and did mot require a chemotactic gradient. The plasminogen-enhanced NC cell migration was blocked by aprotinin (a plasmin inhibitor) and was mimicked by the direct addition of plasmin to the NC cells, indicating that the plasminogen effect was mediated through plasmin generation. Furthermore, anticatalytic-uPA antibody blocked the plasminogen-enhanced NC cell migration showing that NC cell-associated uPA activity was required for this effect, Finally, decreasing NC-uPA activity by treating cells with transforming growth factor-beta, also blocked the plasminogen-dependent increase in cell migration, These data show that in vitro, NC cell migration is regulated by NC-associated uPA activity suggesting that growth factor-regulation of this activity may play a major role in regulating NC cell migratory capacity in vivo. (C) 1996 Wiley-Liss, Inc.
引用
收藏
页码:281 / 290
页数:10
相关论文
共 50 条
  • [1] Urokinase-type plasminogen activator expression during early cephalic neural crest migration.
    Brauer, PR
    Agrawal, M
    Hildebrandt, LM
    FASEB JOURNAL, 1998, 12 (04): : A318 - A318
  • [2] Urokinase-type plasminogen activator
    Crippa, Massimo P.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2007, 39 (04): : 690 - 694
  • [3] Urokinase-type plasminogen activator in human gliomas in vitro
    Gillespie, J
    McCormick, D
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1996, 22 (05) : 454 - 454
  • [4] Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia
    Guo, Hong
    Zhou, Lan-Xia
    Ma, Haizhen
    Liu, Bei
    Cheng, Juan
    Ma, Yun-Yun
    Zhao, Li
    ONCOLOGY LETTERS, 2017, 14 (01) : 383 - 389
  • [5] Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system
    Yin, SP
    Lockett, J
    Meng, YH
    Biliran, H
    Blouse, GE
    Li, XH
    Reddy, N
    Zhao, ZM
    Lin, XL
    Anagli, J
    Cher, ML
    Sheng, SJ
    CANCER RESEARCH, 2006, 66 (08) : 4173 - 4181
  • [6] IMPORTANCE OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR RECEPTOR FOR NEUTROPHIL MIGRATION
    PEDERSEN, TL
    PEDERSEN, JO
    RYGAARD, J
    RONNE, E
    GRONDAHLHANSEN, J
    DANO, K
    HANSEN, NE
    PLESNER, T
    BLOOD, 1994, 84 (10) : A32 - A32
  • [7] Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid
    Akinci, Bans
    Terzi, Cem
    Sevindik, Gokmen
    Yuksel, Faize
    Tunc, Ulku Aybuke
    Tunali, Sunay
    Yesil, Sena
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2014, 28 (06) : 844 - 849
  • [8] Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: Correlation with tumor associated macrophage and prognosis
    Ohba, K
    Miyata, Y
    Kanda, S
    Koga, S
    Hayashi, T
    Kanetake, H
    JOURNAL OF UROLOGY, 2005, 174 (02): : 461 - 465
  • [9] Bioluminescence Imaging of Urokinase-Type Plasminogen Activator Activity in Vitro and in Tumors
    Chen, Yinglu
    Wu, Chengfan
    Wang, Chenchen
    Zhang, Tong
    Hua, Yue
    Shen, Yang
    Liang, Gaolin
    ANALYTICAL CHEMISTRY, 2021, 93 (29) : 9970 - 9973
  • [10] Chemotactic effect of urokinase-type plasminogen activator on mouse spermatozoa in vitro
    Ding X.
    Li H.
    Xiong C.
    Frontiers of Medicine in China, 2008, 2 (2): : 195 - 199